New green-field assembly and packing facility in Boufarik, Algeria (LMSB)
Scope of services
As Full-Service Client Consultant for the project Aqvila are responsible for all design services in connection with conceptual design, environmental impact assessment, building permit application and preparation of Tender Documents. These services include project and design management, design of civil, structural and architectural works as well as design of electrical, mechanical and fire protection works. Furthermore, Aqvila’s services include screening and pre-qualification of contractors, tender evaluation, contracting of a FIDIC “Plant and Design-Build” contract as well as construction management and technical follow-up during the entire Construction phase.
In Algeria, it is estimated that nearly 2 million Algerian citizens suffer from diabetes. A figure that is expected to rise to more than 3 million cases by 2040. Consequently, Novo Nordisk made a decision to invest in a new production facility. The facility is expected to start the production of insulin pens and other medicines for diabetes in August 2019, after having faced a number of constraints related to the purchase of the land and lack of water and electricity.
The project will have a production capacity of 45 million units of insulin (in the form of injectable solution in pre-filled pen), with a forecast of creation of 150 direct jobs and 300 indirect jobs.
The facility comprises a gross floor area of approx. 10.205 m² consisting of approx. 2,000 m² Administration building, 3,750 m² Production building, 1,755 m² Warehouse building, 2,460 m² Utility & Dispatch building, guardhouse and an electrical building.